• 1. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 2. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 5. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Tertiary alcohols
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alcohols and polyols Tertiary alcohols

(3αS,7αS)-(+)-Hexahydro-3α-hydroxy-7α-methyl-1,5-indandione (CAS No. 33879-04-8): A Comprehensive Overview

(3αS,7αS)-(+)-Hexahydro-3α-hydroxy-7α-methyl-1,5-indandione (CAS No. 33879-04-8) is a unique and structurally complex compound that has garnered significant attention in the fields of organic chemistry and medicinal chemistry. This compound, characterized by its specific stereochemistry and functional groups, holds potential applications in various areas, including pharmaceutical development and chemical synthesis. This comprehensive overview aims to provide an in-depth understanding of the compound's properties, synthesis methods, biological activities, and recent research advancements.

The chemical structure of (3αS,7αS)-(+)-Hexahydro-3α-hydroxy-7α-methyl-1,5-indandione is notable for its cyclohexane ring fused with a five-membered ring containing a ketone group. The presence of the hydroxyl and methyl groups at specific stereocenters (3α and 7α) imparts unique physical and chemical properties to the molecule. These structural features are crucial for its biological activity and potential therapeutic applications.

In terms of physical properties, (3αS,7αS)-(+)-Hexahydro-3α-hydroxy-7α-methyl-1,5-indandione is a white crystalline solid with a melting point of approximately 150°C. It is soluble in common organic solvents such as ethanol and dichloromethane but has limited solubility in water. These solubility characteristics are important for its use in various chemical reactions and biological assays.

The synthesis of (3αS,7αS)-(+)-Hexahydro-3α-hydroxy-7α-methyl-1,5-indandione has been a subject of extensive research due to its complex structure. One of the most common synthetic routes involves the Diels-Alder reaction followed by selective reduction and oxidation steps to introduce the hydroxyl and methyl groups at the desired positions. Recent advancements in asymmetric synthesis have also led to more efficient and enantioselective methods for producing this compound with high purity and yield.

Biological studies have revealed that (3αS,7αS)-(+)-Hexahydro-3α-hydroxy-7α-methyl-1,5-indandione exhibits a range of pharmacological activities. One of the most promising areas of research is its potential as an anti-inflammatory agent. In vitro studies have shown that this compound can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6 in macrophages. Additionally, it has demonstrated anti-proliferative effects on cancer cells, particularly in breast and colon cancer cell lines.

Recent clinical trials have further explored the therapeutic potential of (3αS,7αS)-(+)-Hexahydro-3α-hydroxy-7α-methyl-1,5-indandione. Preliminary results from phase I trials indicate that it is well-tolerated with minimal side effects at therapeutic doses. These findings have paved the way for more advanced clinical studies to evaluate its efficacy in treating inflammatory diseases and certain types of cancer.

Beyond its therapeutic applications, (3αS,7αS)-(+)-Hexahydro-3α-hydroxy-7α-methyl-1,5-indandione has also found use as a valuable building block in organic synthesis. Its unique structure makes it an excellent starting material for the synthesis of more complex molecules with diverse biological activities. Researchers have utilized this compound to develop novel derivatives with enhanced pharmacological properties.

In conclusion, (3αS,7αS)-(+)-Hexahydro-3α-hydroxy-7α-methyl-1,5-indandione (CAS No. 33879-04-8) is a multifaceted compound with significant potential in both pharmaceutical development and chemical synthesis. Ongoing research continues to uncover new applications and optimize synthetic methods for this intriguing molecule. As our understanding of its properties and biological activities deepens, it is likely that (3αS,7αS)-(+)-Hexahydro-3α-hydroxy-7α-methyl-1,5-indandione will play an increasingly important role in advancing medical treatments and chemical innovations.

• 521-11-9(Mestanolone)
• 58-19-5(Dromostanolone)
• 1911-78-0(Oplopanone)
• 3381-88-2(Methasterone)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)